Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for cardiopulmonary diseases, with a focus on pulmonary arterial hypertension (PAH). The company's lead product candidate, IKT-001, is a novel oral prodrug formulation of imatinib designed to maintain the efficacy of this established kinase inhibitor while reducing gastrointestinal side effects that limit patient adherence, targeting an unmet need in a rare disease market where existing therapies primarily function as vasodilators rather than addressing underlying disease mechanisms. The company generates no revenue from product sales but aims to advance IKT-001 through clinical development toward regulatory approval and potential commercialization, with global rights to the candidate and patent protection extending through the 2030s to 2040s.